Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ampio Pharmaceuticals will present the data of the study involving its drug candidate, Ampion to address human inflammation, at the American Association of Orthopedic Surgery( AAOS) meeting in February 2012.
Subscribe to our email newsletter
Ampion is a small molecule with non-steroidal anti-inflammatory and analgesic properties that is naturally produced by humans in response to injury.
The molecule is formed from the cleavage and cyclization of the N- terminal amino acids of human serum albumin in-vivo as a biological compound.
The study demonstrated that the presence of Ampionin in biofilms found on extracted orthopedic devices suggests innate human physiologic mechanisms conferring tolerance to the implanted device.